

From: [Wozniak, Jon](#)
To: [AGO - High Cost Prescription Drugs](#)
Cc: [Papandrikos, Gus](#); [McCormick, Albert](#)
Subject: Notice of Introduction of New High-Cost Prescription Drugs
Date: Tuesday, August 13, 2019 1:36:27 PM

Good Afternoon,

Pursuant to 18 V.S.A. § 4637 (Notice of Introduction of New High-Cost Prescription Drugs), Daiichi Sankyo, Inc. is writing to notify the Office of the Attorney General in writing of the introduction of a new prescription drug to market at a wholesale acquisition cost that exceeds the threshold set for a specialty drug under the Medicare Part D program.

Brand Name: Turalio
Chemical Name: Pexidartinib

Not later than 30 days from today, Daiichi Sankyo, Inc. will provide the AGO with the additionally required information from § 4637 subsection C which is in the public domain or otherwise publicly available.

Please let me know if there are any questions or issues.

Thank you,
Jon

Jonathan Wozniak
Associate Director – Compliance Monitoring & Transparency Reporting
Daiichi Sankyo, Inc.
211 Mt. Airy Rd
Basking Ridge, NJ 07920 • USA
Direct +1 908 992 6655
Mobile +1 201 317 6788
jwozniak@dsi.com
www.dsi.com
Passion for Innovation
Compassion for Patients